# Zumutor Biologics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zumutor-biologics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.zumutor.com
- Total disclosed funding: $18M
- Latest round: Series A (Jun 13, 2026)
- Investors on record: 4

## About

Zumutor Biologics Inc. is a US-based biotechnology firm focused on developing innovative NK cell therapeutics to enhance innate immunity and target tumors effectively. Founded in 2013 and headquartered in Cambridge, Massachusetts, Zumutor Biologics specializes in NK cell therapeutics. Kavitha Rodrigues, the CEO and founder, has directed the company's focus toward proprietary therapeutic advancements. In June 2026, Zumutor Biologics Inc. raised USD 7.3 million in pre-series B funding co-led by Accel, bharat innovation fund and Premjiminvest. 

Zumutor Biologics specializes in developing targeted NK cell therapeutics, utilizing its Human Antibody platform, INABLR®. The lead product, the Anti-LLT1 monoclonal antibody, targets LLT1 for treating malignancies such as prostate cancer, B-cell lymphoma, and glioblastoma. The company operates R&D facilities in Cambridge, Massachusetts, and Bangalore, India, aiming to enhance patient outcomes through targeted therapies in oncology and immune-mediated diseases. Zumutor Biologics generates revenue primarily through partnerships and collaborations with healthcare institutions and pharmaceutical companies, utilizing licensing agreements and service contracts for clinical testing of its monoclonal antibodies. Financial specifics regarding individual products have not been disclosed, yet the Anti-LLT1 mAb is expected to significantly impact future revenue as it advances in clinical trials.

The company will use the June 2026 funding to complete the ongoing US FDA Phase 1 clinical trial of ZM008, support Phase 1B expansion cohorts, and initiate global Phase 2 studies, including in India.

## Funding rounds

- Series A, Jun 13, 2026, $7.3M — Accel, Bharat Innovation Fund, Premji Invest
- Series A, Dec 9, 2021, $6.2M — Accel, Bharat Innovation Fund, Siana Capital Management
- Series A, Nov 27, 2019, $4M — Accel, Bharat Innovation Fund

## Investors

- Accel (https://capitalatlas.ai/funds/accel) — Series A
- Bharat Innovation Fund (https://capitalatlas.ai/funds/bharat-innovation-fund) — Series A
- Siana Capital Management (https://capitalatlas.ai/funds/siana-capital-management) — Series A
- Premji Invest — Series A